Schedule 13G ownership disclosure
Coya Therapeutics Inc
Common Stock, par value $0.0001 per share · CUSIP: 22407B108
Event date: 2024-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- DME Capital Management, LP
Shares: 1,267,669 · Class: 7.6%
- DME Advisors, LP
Shares: 383,771 · Class: 2.3%
- DME Advisors GP, L.L.C.
Shares: 1,651,440 · Class: 9.9%
- EINHORN DAVID
Shares: 1,651,440 · Class: 9.9%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000929638-25-000790
- Form type
- SCHEDULE 13G/A
- Filer
- Coya Therapeutics, Inc.
- CIK
- CIK 1835022
- Filed
- Feb 14, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership